Risedronate Sodium



Risedronate Sodium





(rah sed’ dro nate)

Actonel, AtelviaDNC

PREGNANCY CATEGORY C


Drug Class

Bisphosphonate


Therapeutic Actions

Affects osteoclast activity by reducing the enzymatic and transport processes that lead to resorption of the bone and by inhibiting the osteoclast proton pump, leading to a rate of bone turnover near normal in patients with Paget disease and decreasing the elevated rate of bone turnover in postmenopausal osteoporosis.


Indications



  • Treatment of Paget disease of bone


  • Treatment and prevention of osteoporosis in postmenopausal women


  • Treatment and prevention of glucocorticoid-induced osteoporosis


  • To increase bone mass in men with osteoporosis



Available Forms

Tablets—5, 30, 35, 75 (CAN), 150 mg; DR tabletsDNC—35 mg


Dosages

Adults



  • Treatment and prevention of postmenopausal osteoporosis: 5 mg PO once daily taken in an upright position with 6–8 oz of water at least 30 min before or after any other beverage or food. For postmenopausal osteoporosis, may switch to 35-mg tablet or 35-mg DR tablet taken PO once per wk or 75 mg PO taken on 2 consecutive days each mo (total of 2 tablets per mo) or one 150-mg tablet PO per mo.


  • Treatment or prevention of glucocorticoid osteoporosis: 5 mg/day PO.


  • Paget disease: 30 mg PO once daily for 2 mo taken in an upright position with 6–8 oz of plain water at least 30 min before or after any other beverage or food; may retreat after at least a 2-mo post-treatment period if indicated.


  • To increase bone mass in men with osteoporosis: 35 mg PO once/wk.

    Only gold members can continue reading. Log In or Register to continue

    Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Risedronate Sodium

Full access? Get Clinical Tree

Get Clinical Tree app for offline access